<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201614</url>
  </required_header>
  <id_info>
    <org_study_id>RL 04</org_study_id>
    <nct_id>NCT03201614</nct_id>
  </id_info>
  <brief_title>Comparative Evaluation of A-CP HA Kit, Hyaluronic Acid and Placebo for the Treatment of Knee Osteoarthritis</brief_title>
  <official_title>Comparative Evaluation of the Performance and Safety of A-CP HA Kit, for the Preparation of a Combination of Platelet Rich Plasma and Hyaluronic Acid, Versus Hyaluronic Acid Alone and Placebo in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regen Lab SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regen Lab SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyaluronic acid (HA) is a major component of synovial fluid, to which it confers viscosity&#xD;
      and elasticity. It has been shown that the rheological properties of the synovial fluid&#xD;
      decrease in patients with osteoarthritis. Intra-articular injections of hyaluronic acid&#xD;
      represents a commonly used therapeutic option to relieve osteoarthritic symptoms, by exerting&#xD;
      a mechanical action on cartilaginous structures of the joints, thus leading to reduced pain&#xD;
      and improved joint function.&#xD;
&#xD;
      Platelet-rich Plasma is an autologous product prepared from the patient's own blood.&#xD;
      Potential benefits of platelet-rich plasma for the treatment of cartilage defects have been&#xD;
      suggested by many in vitro and animal studies. There are an increasing number of clinical&#xD;
      studies assessing the benefits of platelet rich plasma in the treatment of osteoarthritis,&#xD;
      showing that platelet rich plasma improves symptoms with no serious adverse events reported.&#xD;
&#xD;
      On the basis of the above, HA and platelet-rich plasma have the potential to provide added&#xD;
      benefits in osteoarthritis symptoms when combined, in particular in patients who have had&#xD;
      previous intra-articular HA treatment but who are still experiencing pain. Preliminary&#xD;
      evidence to this effect was presented at the 2014 Annual Congress of the French Rheumatology&#xD;
      Society by a group of French investigators. Renevier and Marc enrolled patients who had not&#xD;
      experienced adequate symptom relief from previous intra-articular HA treatment and treated&#xD;
      them with HA plus platelet-rich plasma prepared using A-CP HA Kit. Of the 71 patients&#xD;
      treated, approximately 90% were classified as responders based on the OMERACT-OARSI criteria.&#xD;
&#xD;
      The A-CP HA Kit allows for the preparation of a homogenous solution of platelet-rich plasma&#xD;
      and HA, intended to be injected intra-articularly for the treatment of pain in&#xD;
      osteoarthritis. In patients who had previous intra-articular HA treatment but who are still&#xD;
      experiencing pain, treatment with HA plus platelet rich plasma could provide a safe and&#xD;
      reproducible option before surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis (OA) is a degenerative disease of the joint cartilage. The evolution of this&#xD;
      condition is characterized by the following symptoms: pain, joint cracking/popping,&#xD;
      stiffness, deformity, loss of mobility and especially in the case of knee osteoarthritis,&#xD;
      swelling (synovial effusion).&#xD;
&#xD;
      Osteoarthritis can lead to functional impairment and deformities thereby causing degradation&#xD;
      of quality of life and may result in disabilities. Due to the fact that the knees and hips&#xD;
      are weight bearing, osteoarthritis of these joints is often more disabling for persons who&#xD;
      are affected by this condition.&#xD;
&#xD;
      Osteoarthritis is the most common joint disorder in the United States. Among adults 60 years&#xD;
      of age or older, the prevalence of symptomatic knee osteoarthritis is approximately 10% in&#xD;
      men and 13% in women. The number of people affected with symptomatic OA is likely to increase&#xD;
      due to the aging of the population and the obesity epidemic.&#xD;
&#xD;
      A healthy joint is composed of two bone ends covered by cartilage (hyaline cartilage). This&#xD;
      allows for shock absorption and for the bones to slide over one another with ease, thus&#xD;
      ensuring the joint mobility. Synovial fluid (synovium) that surrounds the cartilage acts as&#xD;
      lubrication and nutrition for the articular cartilage. It is mainly composed of hyaluronic&#xD;
      acid, a glycosaminoglycan which binds to water molecules which in turn will result in a very&#xD;
      viscous solution thereby giving the synovial fluid its shock absorbing properties. It has&#xD;
      been shown that the rheological properties of synovial fluid decrease with age and in&#xD;
      patients suffering from osteoarthritis, which may cause symptoms of pain and physical loss of&#xD;
      function as seen in gonarthrosis, for example.&#xD;
&#xD;
      Osteoarthritis has multiple causative agents, many of which are not yet fully understood.&#xD;
      However, a number of risk factors including age, gender, genetics, obesity, joint trauma,&#xD;
      certain sports or professional activities are currently known. Conventionally, there is a&#xD;
      distinction between so-called primary osteoarthritis, for which there is no obvious&#xD;
      predisposition (of unknown origin) and secondary osteoarthritis, related to previous trauma&#xD;
      or joint diseases. The secondary type represents the most common form of osteoarthritis.&#xD;
&#xD;
      There are many and varied possibilities for treating gonarthrosis which include both&#xD;
      medicated and non-medicated routes. Among these, physical therapy and an improved life style&#xD;
      (weight loss, use of suitable shoe inserts, regular physical activity etc.) are an essential&#xD;
      component in the management of knee osteoarthritis.&#xD;
&#xD;
      In terms of medication, the administration of analgesics and non-steroidal anti-inflammatory&#xD;
      drugs (NSAIDs) is the standard treatment. However, although they promptly act against pain&#xD;
      and inflammation, they only have a limited effect over time in treating the symptoms without&#xD;
      acting upon the cause.&#xD;
&#xD;
      Slow acting anti-rheumatic drugs, including glucosamine, chondroitin sulphate, diacerhein,&#xD;
      soybean and avocado unsaponifiables on the contrary have a delayed action on the pain and&#xD;
      joint function. Although still widely used in clinical practice for their chondroprotective&#xD;
      effect, they have moderate efficacy and primarily allow for the reduction of analgesic and&#xD;
      anti-inflammatory drug doses.&#xD;
&#xD;
      Corticoid infiltrations occupy an important place in the therapeutic range of osteoarthritis,&#xD;
      especially when analgesics and anti-inflammatory drugs fail to relieve an inflammatory flare.&#xD;
      The observed effect, however, has a limited effect over time.&#xD;
&#xD;
      Intra-articular injections of hyaluronic acid (viscosupplementation treatment) are currently&#xD;
      the treatment of choice in gonarthrosis as they can relieve symptoms for several months at a&#xD;
      time. These are designed to exert a mechanical action on cartilaginous structures of the&#xD;
      joints, leading to a reduction in pain and improvement in the joint function. The&#xD;
      effectiveness of hyaluronic acid is widely documented. Indeed, many clinical trials testing&#xD;
      different hyaluronic acid preparations have been carried out in humans, some of which report&#xD;
      results versus a saline placebo. Most of these studies conclude to the superiority of&#xD;
      hyaluronic acid regardless of its molecular weight.&#xD;
&#xD;
      More recently, the injections of platelet rich plasma were found to be an attractive&#xD;
      treatment option, due to the autologous nature of the product and its mechanism of action.&#xD;
      Indeed, the action of platelet rich plasma is not based on sustainable viscoelasticity of the&#xD;
      product, but on biological stimulation of mesenchymal stem cells (MSCs) and cartilaginous&#xD;
      cells. Many in vitro studies have already demonstrated the effects of isolated growth factors&#xD;
      on stimulation and chondrogenic differentiation of mesenchymal stem cells.&#xD;
&#xD;
      The clinical use of isolated growth factors is impossible today with regard to their mode of&#xD;
      production and the potential risk to human health. The autologous platelet rich plasma is the&#xD;
      simplest and safest solution to provide usable growth factors in a clinical setting. The&#xD;
      interest and potential efficacy of platelet-rich plasma in the treatment of cartilage lesions&#xD;
      have already been tested in vitro:&#xD;
&#xD;
        -  Platelet-rich plasma increases the synthesis of proteoglycans and collagen in the&#xD;
           extracellular matrix of cultured intervertebral disc cells&#xD;
&#xD;
        -  Platelet-rich plasma stimulates the proliferation and biosynthesis of the matrix of&#xD;
           articular chondrocytes in pigs&#xD;
&#xD;
        -  Platelet-rich plasma increases the expression of the &quot;cartilage oligomeric matrix&#xD;
           protein&quot; (COMP) Platelet-rich plasma was superior to a standard culture medium in the&#xD;
           proliferation and differentiation of mesenchymal stem cells into chondrocytes At the&#xD;
           clinical level, a number of studies showed improved symptoms with no serious adverse&#xD;
           effects. When compared to hyaluronic acid injections, platelet-rich plasma treatment&#xD;
           demonstrated superiority in terms of reduced pain, stiffness and function.&#xD;
&#xD;
      These results suggest that platelet-rich plasma, by its specific mechanism of action, is an&#xD;
      effective and innovative tool in the therapeutic arsenal for the treatment of symptomatic&#xD;
      gonarthrosis.&#xD;
&#xD;
      On the basis o the above, it is reasonable to assume that platelet-rich plasma and hyaluronic&#xD;
      acid have the potential to provide added benefits in osteoarthritis when combined, in&#xD;
      particular in patients who have had previous intra-articular HA treatment but who are still&#xD;
      experiencing pain. Preliminary evidence to this effect was presented at the 2014 Annual&#xD;
      Congress of the French Rheumatology Society by a group of French investigators. Renevier and&#xD;
      Marc enrolled patients who had not experienced adequate symptom relief from previous&#xD;
      intra-articular HA treatment and treated them with the combination of platelet rich plasma&#xD;
      and HA prepared using A-CP HA Kit. Of the 71 patients treated approximately 90% were&#xD;
      classified as responders based on the OMERACT-OARSI criteria.&#xD;
&#xD;
      The A-CP HA Kit, manufactured by Regen Lab SA, Le Mont-sur-Lausanne, VD, Switzerland, allows&#xD;
      for the preparation of a homogenous solution of platelet-rich plasma and HA. The product is&#xD;
      intended to be injected intra-articularly for the symptomatic treatment of pain. In patients&#xD;
      who had previous intra-articular HA treatment but who are still experiencing pain, treatment&#xD;
      with HA plus platelet-rich plasma could provide a safe and reproducible option before&#xD;
      surgery.&#xD;
&#xD;
      The objective of this study is to investigate if a biological treatment based on a&#xD;
      combination of platelet-rich plasma and hyaluronic acid obtained with A-CP HA Kit is&#xD;
      statistically superior to HA alone, on one hand, and to a saline placebo, on the other hand,&#xD;
      to reduce overall knee osteoarthritis symptoms, and particularly pain, and thus improve&#xD;
      quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2018</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation in overall OA-related symptoms</measure>
    <time_frame>6 Months</time_frame>
    <description>It will be assessed by the mean difference in total WOMAC score on a 100-mm VAS between baseline and Month 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation in pain at walking (WOMAC A1 score)</measure>
    <time_frame>6 Months</time_frame>
    <description>II t will be assessed by the mean difference on a 100-mm VAS between baseline (D0) and Month 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation in overall OA-related symptoms, between baseline (D0) and Month 1 (D30), Month 2, Month 3, Month 4, and Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>It will be assessed by the mean difference in total WOMAC score on a 100-mm VAS between baseline (D0) and Month 1, Month 2, Month 3, Month 4, and month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in pain at walking (WOMAC A1 score), between baseline (D0) and Month 1 (Day 30), Month 2, Month 3, Month 4, and Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>It will be assessed by the mean difference in WOMAC A1 score on a 100-mm VAS between baseline (D0) and Month 1 (Day 30), Month 2, Month 3, Month 4, and Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of general pain, between baseline (D0) and Month 1 (Day 30), Month 2, Month 3, Month 4, Month 6 and Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>It will be assessed by the mean difference in total WOMAC A score on a 100-mm VAS between baseline (D0) and Month 1 (Day 30), Month 2, Month 3, Month 4, Month 6 and Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of joint stiffness, between baseline (D0) and Month 1 (Day 30), Month 2, Month 3, Month 4, Month 6 and Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>It will be assessed by the mean difference in total WOMAC B score on a 100-mm VAS between baseline (D0) and Month 1 (Day 30), Month 2, Month 3, Month 4, Month 6 and Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of joint function, between baseline (D0) and Month 1 (Day 30), Month 2, Month 3, Month 4, Month 6 and Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>It will be assessed by the mean difference in total WOMAC C score on a 100-mm VAS between baseline (D0) and Month 1 (Day 30), Month 2, Month 3, Month 4, Month 6 and Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of OMERACT-OARSI responders</measure>
    <time_frame>12 Months</time_frame>
    <description>It will be assessed at Month 1, Month 2, Mont 3, Month 4, Month 6, and Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global assessment on a 7-point scale</measure>
    <time_frame>12 Months</time_frame>
    <description>It will be assessed at Month 1, Month 2, Mont 3, Month 4, Month 6, and Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global assessment on a 7-point scale at Month 1 (D30), Month 2, Mont 3, Month 4, Month 6, and Month 12 Clinician's global assessment on a 7-point scale</measure>
    <time_frame>12 Months</time_frame>
    <description>It will be assessed at Month 1, Month 2, Mont 3, Month 4, Month 6, and Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of the patient's quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>It will be assessed by the variation in the SF-36 questionnaire, between baseline (D0) and Month 1 (Day 30), Month 2, Month 3, Month 4, Month 6 and Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication</measure>
    <time_frame>12 Months</time_frame>
    <description>Comparison of the use of rescue medication between the three groups of treatment at baseline, Month 1, Month 2, Month 3, Month 4, Month 6 and Month 12</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>A-CP HA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized in this group will be treated with a combination of platelet-rich plasma plus hyaluronic acid prepared with A-CP HA Kit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ArthroVisc 40</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized in this group will be treated with hyaluronic acid only (ArthroVisc 40); hyaluronic acid is the same as the one contained in the A-CP HA Kit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized in this group will be treated with a saline solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>A-CP HA Kit</intervention_name>
    <description>Patients randomized in this group will receive two injections of platelet-rich plasma/hyaluronic acid prepared with the A-CP HA Kit at Day 0 and Month 2</description>
    <arm_group_label>A-CP HA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ArthroVisc 40</intervention_name>
    <description>Patients randomized in this group will receive two injections of hyaluronic acid only (ArthroVisc 40) at Day 0 and Month 2</description>
    <arm_group_label>ArthroVisc 40</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients randomized in this group will receive two injections of a saline placebo at Day 0 and Month 2</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Osteoarthritis grade 2-3 according to the Kellgren &amp; Lawrence grading scale, as&#xD;
             defined on knee radiographs (less than 3 months old: face view, schuss view, profile&#xD;
             and patellar axial view at 30Â°)&#xD;
&#xD;
          -  Knee Pain level of at least 3 on the 0-10-point WOMAC A subscale&#xD;
&#xD;
          -  Bilateral osteoarthritis provided that the contralateral knee has a pain no more than&#xD;
             2 on the 0-10 point scale, and not requiring systemic analgesic treatment except&#xD;
             paracetamol until the maximum dose of 4g per day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Grade &lt;2 or &gt;3 OA according to the Kellgren and Lawrence grading scale&#xD;
&#xD;
          -  Bilateral osteoarthritis provided that the contralateral knee has a pain more than 2&#xD;
             on the 0-10 point scale and requiring systemic analgesic treatment or paracetamol more&#xD;
             than 4g per day&#xD;
&#xD;
          -  Viscosupplementation in the treatment site in the past 3 months&#xD;
&#xD;
          -  Corticosteroid injection in the treatment site in the previous 3 months&#xD;
&#xD;
          -  Systematic use of corticosteroid (except those that are inhaled) within 3 months&#xD;
&#xD;
          -  History of allergy to hyaluronic acid&#xD;
&#xD;
          -  Rheumatological disorders&#xD;
&#xD;
          -  Clinical evidence of local inflammation such as redness or heat of the joint&#xD;
&#xD;
          -  Current or medical history of autoimmune disease&#xD;
&#xD;
          -  Surgery or arthroscopy surgery in the affected knee in the past 3 months&#xD;
&#xD;
          -  Local infection in the affected knee&#xD;
&#xD;
          -  Hematologic or clotting disorders (thrombocytopenia) or blood coagulation&#xD;
             (deficit-blood dyscrasia)&#xD;
&#xD;
          -  Anaemia (Haemoglobin &lt; 10g/dl)&#xD;
&#xD;
          -  Platelet count below 150/mmc&#xD;
&#xD;
          -  Anticoagulant treatment&#xD;
&#xD;
          -  Viral disease (hepatitis, herpes, varicella, zona, etc.)&#xD;
&#xD;
          -  Renal failure or hemodialysis&#xD;
&#xD;
          -  Acute infection&#xD;
&#xD;
          -  Immunosuppressive states&#xD;
&#xD;
          -  Malignant disease&#xD;
&#xD;
          -  Recent fever (within previous 2 weeks) or serious disorders (liver disease, active&#xD;
             gastroduodenal ulcer, digestive hemorrhage, etc.)&#xD;
&#xD;
          -  Pregnancy or breastfeeding or planning pregnancy during the course of the study&#xD;
&#xD;
          -  Immunosuppressants within the past 6 weeks or ongoing&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Participation in another clinical study in the past 3 months&#xD;
&#xD;
          -  Ongoing participation in another OA clinical study&#xD;
&#xD;
          -  Fracture, skeletal dysplasia, congenital or acquired deformity that affects the knee&#xD;
&#xD;
          -  Hemoglobin A1C &gt; 8% within 8 weeks prior to the study treatment&#xD;
&#xD;
          -  Have been given the diagnosis of fibromyalagia, neuropathic pain syndrome, or&#xD;
             depression&#xD;
&#xD;
          -  Refusal to sign or inability to give Informed Consent&#xD;
&#xD;
          -  Inability to understand or comply with the requirements of the study&#xD;
&#xD;
          -  Any other reason which may interfere with the proper conduct of the study, in the&#xD;
             investigator's opinion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bert Mandelbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Santa Monica Orthopaedic &amp; Sports Medicine Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicholas Sgaglione, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerie De Fourmestraux, PhD</last_name>
    <phone>+41(0)21 864 01 18</phone>
    <email>vdefourmestraux@regenlab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bert Mandelbaum, MD</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>platelet-rich plasma, hyaluronic acid, knee osteroarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

